Assessment of hormone refractory prostate cancer

Urology

Volumn 49, Issue 4 SUPPL., 1997, Pages 46-53

  Newling, Don ^a,k   Fosså, Sophie D ^b   Andersson, Lennart ^c   Abrahamsson, Per Anders ^d   Aso, Yoshio ^e   Eisenberger, Mario A ^f   Khoury, Saad ^g   Kozlowski, James S ^h   Kelly, Kevin ⁱ   Scher, Howard ⁱ   Hartley Asp, Beryl ^j  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e FUJIEDA MUNICIPAL GENERAL HOSPITAL   (Japan)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j Pharmacia & Upjohn AB   (Sweden)

^k VU UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PAIN; CANCER RESEARCH; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT OUTCOME;

EID: 0030904147     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)80323-9     Document Type: Article

References (25)

1. Eisenberger MA: Chemotherapy for endocrine resistant cancer of the prostate, in Schröder FH (Ed.): Treatment of Prostate Cancer - Facts and Controversies. New York, Wiley-Liss, 1990, pp 155-164.
2. Klijn JGM: Scientific background of hormonal treatment of prostate cancer, in Newling DW, and Jones WG (Eds.): Prostate Cancer and Testicular Cancer. New York, Wiley-Liss, 1990, pp 7-22.
3. Kuil CW, and Brinkmann AO: Androgens, anti-androgens and androgen receptor abnormalities. Eur Urol 29: 78-82, 1996.
4. Keuppens F, Fosså SD, Nowé P, and Denis L: Secondary orchiectomy in patients with prostatic cancer in relapse, in Denis L, Murphy GP, Pout GR, (Eds.): Controlled Clinical Trials in Urological Oncology. New York, Raven Press, 1984, pp 207-211.
5. Collste LG: Second line treatment of hormone refractory prostate cancer patients, in Newling DW, and Jones WG (Eds.): Prostate Cancer and Testicular Cancer. New York, Wiley-Liss, 1990, pp 29-37.
6. Prostate Cancer Trialists Collaboration Group (1995). Maximum androgen blockade in advanced prostate cancer. -An overview of 22 randomized trials with 3,283 deaths in 5,710 patients. The Lancet 346: 265-269.
7. Scher HI, Mazumdar M, and Kelly WK: Clinical trials in relapsed prostate cancer: defining the target. J Nat Cancer Inst 88: 1623-1634.
8. Newling DW, Denis L, and Vermeylen K: Orchiectomy vs goserelin and flutamide in the treatment of newly metastatic diagnosed prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer - Genitourinary Group Study. Cancer 72: 3793-3798, 1993.
9. Jones WG, Alasa H, van Ooosterom A, and Kotake T: Objective response criteria in phase II and phase III studies, in Schröder FH, Klijn JGM, Kurth KH, Pinedo HM, Splinter TAW, and de Voogt HJ (Eds.): Progress and Controversies in Urologie Oncology II. New York, Alan R. Liss, 1988, pp 243-261.
10. Smith PH, Debruyne FMJ, Armitage TG, Hall RR, Bono A, Denis L, and Sylvester R: The value of bone scan, in Newling DW, and Jones WG (Eds.): Prostate Cancer and Testis Cancer. New York, Wiley-Liss, 1990, pp 53-57.
11. Newling DW: Parameters of response and progression in prostate cancer, in Schröder FH (Ed.): Treatment of Prostate Cancer - Facts and Controversies. New York, Wiley-Liss, 1990, pp 25-48.
12. Eisenberger MA, and Nelson WG: How much can we rely on the level of PSA as an endpoint for evaluation of clinical trials? A word of caution! J Natl Cancer Inst 88: 779-781, 1996.
13. Thalmann GN, Sikes RA, Chang SM, Johnston DA, von Eschenbach AC, and Chung LW: Suramin induced decrease in PSA expression with no effect on tumor growth in the LnCaP model of human prostate cancer. J Natl Cancer Inst 88: 794-801, 1996.
14. Wilding G, quoted in Eisenberger MA, and Nelson WG: How much can we rely on PSA as an endpoint for evaluation of clinical trials? A word of caution? J Natl Cancer Inst 88: 779-781, 1996.
15. Coffey DS, and Isaacs JT: Experimental Concepts in the Design of New Treatments for Human Prostate Cancer. UICC Technical Report. Geneva, International Union Against Cancer (UICC), 1979, pp 233-239.
16. Scher HI and Kelly WK: Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 11: 1566-1572, 1993.
17. Ferro MA: Use of intravenous stilbestrol in patients with prostatic cancer refractory to conventional hormonal manipulation. Urol Clin North Am 18: 139-143, 1991.
18. Fosså SD, Jahnsen JK, and Karlsen S, et al: High dose MPA vs prednisolone in hormone resistant prostatic cancer. A pilot study. Eur Urol 11: 11-16, 1985.
19. Mahler C, and Denis L: Treatment of hormone refractory disease. Semin Surg Oncol 11: 770-783, 1995.
20. Eisenberger MA, Reyno LM, Jodrell DI, and Sinibaldi OJ, et al: Suramin - an active drug for prostate cancer - interim observation in a phase I trial. J Natl Cancer Inst 85: 611-621, 1993.
21. Maulard C, Richard P, Droz JP, Jessueld D, Thomas F, and Housset M: A phase I/II study of the somatostatin analogue somatatin in hormone refractory prostate cancer. Eur J Cancer 29A: 327-328, 1993.
22. b expression (abst). J Urol 155(5, suppl): 192, 1996.
23. Ferrer FA, Miller LJ, and Andoawir RI, et al: Cytokine regulation of angiogenesis factors in human prostate cancer (abst). J Urol 155(5, suppl): 189, 1996.
24. Ko ASC, Gotok L, Kao C, and Chung LWK, et al: Tissue targeted toxic gene therapy for an androgen-independent and metastatic human prostate cancer model (abst). J Urol 155(5, suppl): 202, 1996.
25. Fosså SD: Quality of life after palliative radiotherapy in patients with homone resistant prostate cancer: single institution experience. Br J Urol 74: 345-351, 1994.